Valence ロゴ
人気
ログイン
Loading data for RNXT — first visit, this takes a few seconds.

ウォッチリストに追加

RenovoRx Inc.

NasdaqCM: RNXT · リアルタイム株価 · USD
1.40
+0.14 (11.11%)
終値時点： Aug 19, 2026, 8:00 PM

RenovoRx Inc. (RNXT) Stock Price, Analysis & Data

11.11%

データがありません

買気配1.02
時価総額59.35M
売上高（TTM）1.98M
純利益（TTM）-12.29M
ベータ0.99
EPS（TTM）-0.35
PER（TTM）n/a
予想PER-8.48
PBR（TTM）6.61
PSR（TTM）30.03
Earnings DateAug 14, 2025
売気配1.62
出来高1,001,657
平均出来高（20日）294,308
始値1.27
前日終値1.26
当日レンジ1.26 - 1.45
52週レンジ0.70 - 1.45
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

RNXTについて

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, Calif...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Aug 26, 2021
従業員数 17
上場取引所 NasdaqCM
ティッカー RNXT
ウェブサイト https://renovorx.com
企業情報の全文

業績

2025年のRenovoRxの売上高は1.12Mで、前年の43Kから2,511.63%の増加でした。 利益は-11.17Mで、26.71%の増加でした。

財務諸表

決算サプライズ

RenovoRxはMay 14, 2026に四半期決算を発表しました：
  • 売上高は $563K で、予想を下回りました $0, うち 185.79% の前年比増加にあたります.
  • EPSは -0.08 で、予想を下回りました 0.00, うち 0.00% の前年比増加にあたります.

    • 次回決算発表

    RenovoRx Inc.の決算発表予定日は Aug 14, 2025, 引け後の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1週間前 · Zacks

    Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

    Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    1週間前 · Benzinga

    EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

    RenovoRx, Inc. (NASDAQ:RNXT) announced Tuesday that it has completed patient enrollment for its Phase 3 TIGeR-PaC study of its targeted drug delivery platform for locally advanced pancreatic cancer (L...

    news image

    1週間前 · Zacks

    Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

    Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

    news image

    1週間前 · Zacks

    Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

    Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    2週間前 · Zacks

    Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

    Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    2ページ中1ページ